Loading...

Botanix Pharmaceuticals Limited

BOT.AX•ASX
HealthcareBiotechnology
$0.41
$-0.06(-12.90%)

Botanix Pharmaceuticals Limited (BOT.AX) Stock Overview

Explore Botanix Pharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-34.23%
↓ 34.23%
Profit Growth
$-0.02
↓ 51.52%
EPS Growth
$-0.02
↓ 16.46%
Operating Margin
-1924.58%
↓ 14.88%
ROE
-39.05%
↓ 51.52%
Dividend Yield
0.00%
Analyst Recommendations data is not available for BOT.AXAnalyst Recommendations details for BOT.AX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.

CEO

Dr. Howie McKibbon

Employees

11

Headquarters

D2, 661 Newcastle Street, Leederville, WA

Founded

1988

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.